Published in Lab Business Week, May 21st, 2006
Revenues in fiscal 2005 increased by $8,882,210, or 56.8%, to $24,527,379, versus revenues of $15,645,169 in fiscal 2004. Higher sales volumes for etimicin powder and transfusion products accounted for approximately $6.4 million of the additional revenues.
The company aggressively marketed a new transfusion product, "AIYI," which was first introduced in 2004. Etimicin was also added in 2005 to the National Essential Drugs List, which serves as a purchasing guide for the provinces. The 2004 financial results did not include...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week